5Cheng AL,Kang YK,Chen Z,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trim [ J ]. Lancet Oncol,2009,10 ( 1 ) :25 - 34.
2[2]Lacouture ME.Mechanisms of cutaneous toxicities to EGFR inhibitors.Nat Rev Cancer,2006,6 (10):803
3[3]Agero AL,Dusza SW,Benvenuto-Andrade C,et al.Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.J Am Acad Dermatol,2006,55(4):657
4[4]Rhee J,Oishi K,Garey J,et al.Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents.Clin Colorectal Cancer,2005,5(Suppl 2):S101
6[6]Perez-Soler R,Chachoua A,Hammond LA,et al.Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer.J Clin Oncol,2004,22 (16):3238
7[7]Robert C,Soria JC,Spatz A,et al.Cutaneous side-effects of kinase inhibitors and blocking antibodies.Lancet Oncol,2005,6 (7):491
8[8]Segaert S,Van Cutsem E.Clinical signs,pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.Ann Oncol,2005,16(9):1425
10[10]Mimeault M,Bonenfant D,Batra SK.New advances on the functions of epidermal growth factor receptor and ceramides in skin cell differentiation,disorders and cancers.Skin Pharmacol Physiol,2004,17 (4):153
